Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC

This trial is testing the combination of two cancer drugs — trifluridine/tipiracil (TAS-102) and fruquintinib — as a third-line treatment for people with advanced colorectal cancer (bowel cancer that has spread) whose disease has progressed despite two prior treatment regimens. **You may be eligible if...** - You are between 18 and 75 years old - You have advanced colorectal adenocarcinoma confirmed by tissue biopsy - Your cancer has failed two prior standard treatment regimens - You have at least one measurable tumor - Your organs (blood counts, liver, kidneys, heart) are functioning adequately - You have a good performance status (ECOG 0-1) and a life expectancy of more than 3 months **You may NOT be eligible if...** - You have not yet tried two lines of treatment - You have uncontrolled high blood pressure - You are pregnant or breastfeeding and not willing to use contraception - You have poor organ function (e.g., low blood counts, liver or kidney disease) Talk to your doctor to see if this trial is right for you.